It depends..

- Does the single IRB requirement kick in?
- where are the 'risks'?
- where are the subjects?

John

John R. Baumann, Ph.D.
Associate Vice President for Research Compliance
Office of Research Compliance
Office of Vice President for Research
Indiana University
xxxxxx@iu.edu
317.278.7830 (IUB & IUPUI office)
816.695.7146 (cell)
https://research.iu.edu/compliance/index.html

On 6/21/20, 10:07 PM, "Research Administration List on behalf of Jerrolds, Elsie Audrey Lyn" <xxxxxx@LISTS.HEALTHRESEARCH.ORG on behalf of xxxxxx@ILLINOIS.EDU> wrote:

 This message was sent from a non-IU address. Please exercise caution when clicking links or opening attachments from external sources.
 -------

 Hi Pam,

 Always nice to come across your name here.  I hope all is well.  My initial thought would be that the PI's new institution should review, provide approval and maintain oversight, then I wondered where the majority of work would be done that involves Human Subjects.  Good question.  I'm still going with my initial thought, but am interested in others feedback on this issue.

 Respectfully,

 AUDREY L. JERROLDS, MA, ILLINI CRA
 Grants and Contracts Coordinator

 Coordinated Science Laboratory
 The Grainger College of Engineering | University of Illinois at Urbana-Champaign
 1308 W. Main St. | M/C 228 | Urbana, IL 61801
 217.300.2219 | xxxxxx@illinois.edu
 csl.illinois.edu

 Under the Illinois Freedom of Information Act any written communication to or from university employees regarding university business is a public record and may be subject to public disclosure.

 -----Original Message-----
 From: Research Administration List <xxxxxx@LISTS.HEALTHRESEARCH.ORG> On Behalf Of Vargas, Pamela A
 Sent: Sunday, June 21, 2020 12:27 PM
 To: xxxxxx@LISTS.HEALTHRESEARCH.ORG
 Subject: [RESADM-L] IRB Review When PI is Leaving the Institution

 Hi, all,

 I’m looking for some insight in handling IRB review when the PI is leaving the institution within a few weeks. There will be two collaborators still at the institution, but the lead PI will be working at another institution.

 Would you review and have your institution maintain oversight or would you recommend that the PI work with the new institution’s IRB, especially given that the project has not been reviewed yet?

 Any insight and thoughts are appreciated!

 Thanks,

 Pam

 ############################

 To unsubscribe from the RESADM-L list:
 write to: mailto:xxxxxx@LISTS.HEALTHRESEARCH.ORG
 or click the following link:
 http://lists.healthresearch.org/scripts/wa-HLTHRES.exe?SUBED1=RESADM-L&A=1

 ############################

 To unsubscribe from the RESADM-L list:
 write to: mailto:xxxxxx@LISTS.HEALTHRESEARCH.ORG
 or click the following link:
 http://lists.healthresearch.org/scripts/wa-HLTHRES.exe?SUBED1=RESADM-L&A=1

############################

To unsubscribe from the RESADM-L list:
write to: mailto:xxxxxx@LISTS.HEALTHRESEARCH.ORG
or click the following link:
http://lists.healthresearch.org/scripts/wa-HLTHRES.exe?SUBED1=RESADM-L&A=1